Trial reportPloS one2019
A comparison of dose distributions in gross tumor volume between boron neutron capture therapy alone and combined boron neutron capture therapy plus intensity modulation radiation therapy for head and neck cancer.
Trial report in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Current research trends and hotspots of boron neutron capture therapy: a bibliometric and visualization analysis.Frontiers in oncology · 2024Pooled it
- Development of a scientific version TPS workflow for BNCT dosimetry based on DICOM and Monte Carlo engine.Physical and engineering sciences in medicine · 2026Article
- Taming the Immiscibility of Gold, Iron, and Boron to Craft Chemodegradable Nanoparticles for Multimodal Imaging and Radiotherapy.Advanced healthcare materials · 2026Article
- Advances in Clinical Trials of Boron Neutron Capture Therapy.Research (Washington, D.C.) · 2026Review
- 'Cell knife' for cancer: the clinician's perspective.Frontiers in immunology · 2025Review
- The current status and novel advances of boron neutron capture therapy clinical trials.American journal of cancer research · 2024Review
- Peptide Conjugated Boron Neutron Capture Therapy for Enhanced Tumor Targeting.Nanotheranostics · 2024Review
- Review
- Combined Gadolinium and Boron Neutron Capture Therapies for Eradication of Head-and-Neck Tumor Using GdJACS Au · 2023Article
- Relative biological effectiveness for epithermal neutron beam contaminated with fast neutrons in the linear accelerator-based boron neutron capture therapy system coupled to a solid-state lithium target.Journal of radiation research · 2023Article
- Article
- NeuTHOR Station-A Novel Integrated Platform for Monitoring BNCT Clinical Treatment, Animal and Cell Irradiation Study at THOR.Life (Basel, Switzerland) · 2023Article
- Particle Therapy: Clinical Applications and Biological Effects.Life (Basel, Switzerland) · 2022Review
- Clinical Viability of Boron Neutron Capture Therapy for Personalized Radiation Treatment.Cancers · 2022Review
- Boron Neutron Capture Therapy: A Review of Clinical Applications.Frontiers in oncology · 2021Review
- Boron Chemistry for Medical Applications.Molecules (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nine patients with recurrent head and neck (H&N) cancer received boron neutron capture therapy (BNCT) in one fraction at the Tsing-Hua Open pool reactor (THOR) utilizing the THORplan treatment planning system (TPS). The aims of the present study were to evaluate the use of intensity modulated radiation therapy (IMRT) of 45 Gy in 20 fractions to compensate for the dose heterogeneity in gross tumor volume observed with single-fraction BNCT with mean prescription dose 19 Gy (w), and to evaluate planning quality indices of simulated BNCT+IMRT versus single-fraction BNCT alone. All IMRT plans were generated using the Eclipse TPS which employs the analytical anisotropic algorithm. The conformity index for the gross tumor volume (GTV) was better for the BNCT+IMRT plan than for the BNCT-alone plan (p = 0.003). In addition, the BNCT+IMRT plan provided significantly better homogeneity in the GTV (p = 0.03). The cold spots in inhomogeneous dose distribution in the BNCT plan may be a key factor for H&N cancer recurrence. Our results suggest that single-fraction BNCT combined with compensated multi-fraction IMRT improves treatment homogeneity and conformity than single-fraction BNCT alone, especially for tumor volumes >100 cm3, and possibly increases local tumor control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.